Beckman Coulter Unveils Next Generation Immunoassay Analyzer Enabling Elite Laboratory Performance with No Daily Maintenance

DxI 9000 Access Immunoassay Analyzer Boasts Industry's Highest Throughput per Footprint:
Up To 215 Tests/Hour/Square Meter

Innovations Bolster Assay Performance and Laboratory Productivity with
New Analyte Processing and Detection Technology, Precision Sensors, Smart Algorithms, Remote Real-Time System Monitoring, and is the Only Immunoassay Analyzer with No Daily Maintenance ⁱ

NT-proBNP Assay Now Available with Age-Based Cutoffs and Comorbidity Data

Beckman Coulter, a clinical diagnostics leader, today unveiled the DxI 9000 Access Immunoassay Analyzer, the most productive immunoassay analyzer per footprint. The DxI 9000 Analyzer can run up to 215 tests per hour per square meter (testshrm 2 ).

The DxI 9000 Analyzer innovations address today's speed, reliability, reproducibility, quality, and menu expansion demands. The platform has been independently verified to perform at the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) optimal level, the highest level of EFLM performance evaluation. At the same time, the novel Lumi-Phos PRO Substrate has shown the capability to develop increasingly sensitive and clinically relevant assays, ensuring the system is able to meet the healthcare needs of tomorrow.

According to Julie Sawyer Montgomery , President, Beckman Coulter Diagnostics, "The DxI 9000 Access Immunoassay Analyzer sets new expectations for immunoassay testing operational performance and ability to develop and sustain improved assay sensitivity to meet tomorrow's analytical needs. Those in the laboratory will treasure ZeroDaily Maintenance to save them time, PrecisionVision Technology to safeguard against flawed data reports, and IntelliServe to maximize system uptime. At the same time, clinical researchers are excited about the DxI 9000 Analyzer's capability to keep pace with increasingly sensitive testing requirements as healthcare providers and pharmaceutical companies take aim at ever more challenging diseases. An inspiring feat of technology, the DxI 9000 Analyzer is a comprehensive healthcare innovation."

An early evaluator of the DxI 9000 Analyzer, Dr. Pamela Christudoss , Professor & Head, Department of Clinical Biochemistry, Christian Medical College Vellore, India noted, "Like clinical laboratories worldwide, we are running more tests than any time in our history. The innovations packed into the DxI 9000 Analyzer will enable labs across the globe to improve their throughput rates and turnaround times with worldclass precision. In particular, the team loved the un-paralleled Zero Daily Maintenance especially for a platform that runs 450 tests per hour."

An additional evaluator, Mr. Ray Divilley, Chief Medical Officer, Mayo University Hospital, Ireland , added, "With the DxI 9000, Beckman Coulter has successfully produced a platform that addresses today's laboratories needs for speed, accuracy, and reliability. Based on our use and evaluation of the system in our lab, we were able to get actionable results back quicker to doctors and ultimately patients as they consider treatment options."

ZeroDaily Maintenance highlights the embedded innovations that drive the DxI 9000 Analyzer's uptime performance. Beta users attest to ZeroDaily Maintenance redefining their workday with no daily maintenance requirements, thereby reducing annual maintenance routines by up to 96%.

Building on Beckman Coulter's workflow and automation leadership, PrecisionVision Technology is unmatched in its ability to inspect, identify and prevent erroneous reporting in real time. PrecisionVision automated safeguards include tube identification, cap detection, tip check, sample aspiration, and delivery, residual wash volume, and substrate volume. Each check reduces the risk of reporting flawed data and increases system reliability and reproducibility.

Beckman Coulter's newly designed remote service and diagnostics solution, DxS IntelliServe, connects with DxI 9000 Analyzers to monitor data and error trends, enabling timely, proactive system service when needed. In addition, the DxS IntelliServe solution identifies service experts to resolve issues with real-time monitoring, remote operation, and troubleshooting to maximize laboratory uptime and performance. Equally impactful, IntelliServe's remote update capabilities and proactive scheduling ensures systems are always running on the most up-to-date software, reducing unplanned workflow interruptions or downtime.

Beckman Coulter's Access NT-proBNP assay measures concentrations of N-terminal pro B-type natriuretic peptide that originate in a person's heart. High levels of natriuretic peptides can indicate heart failure. Access NT-proBNP provides rapid results in less than 11 minutes and increases accuracy in diagnosing heart failure with age-based cutoffs and disease-specific comorbidity data for improved test result interpretation.

The DxI 9000 Access Immunoassay Analyzer is currently available in most countries worldwide.

An online news conference will be held on May 17, 2023 . Speakers include Dr. Pamela Christudoss , and Kathleen Orland , Senior Vice President & General Manager, Clinical Chemistry and Immunoassay Business Unit, Beckman Coulter Diagnostics. Qualified journalists and analysts can reach out to mediarelations@beckman.com for a passcode.

Additional Resources

Link to DxI 9000 Access Immunoassay Analyzer media kit
Follow and connect with Beckman Coulter Diagnostics via LinkedIn , Twitter , and Facebook .

About Beckman Coulter, Inc.

A global leader in advanced diagnostics, Beckman Coulter has challenged convention to elevate the diagnostic laboratory's role in improving patient health for more than 80 years. Our mission is to Relentlessly Reimagine Healthcare, One Diagnosis at a Time – and we do this by applying the power of science, technology and the passion and creativity of our teams. Our diagnostic solutions are used in complex clinical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. We exist to deliver smarter, faster diagnostic solutions that move the needle forward from what's now to what's next. We seek to accelerate care with an extensive clinical menu, scalable lab automation technologies, insightful clinical informatics, and optimize lab performance services. Beckman Coulter is part of the Danaher Corporation (NYSE:DHR) family of global science and technology companies. Headquartered in Brea, Calif. , it has more than 11,000 global team members.

© 2023 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. Lumigen and the Lumigen product marks mentioned herein are trademarks or registered trademarks of Lumigen, Inc. in the United States and other countries. Lumigen is a Beckman Coulter company. 2023-11590

ⁱ Based on a comparative review for mid- and high-volume laboratories; data on file.

View original content to download multimedia: https://www.prnewswire.com/news-releases/beckman-coulter-unveils-next-generation-immunoassay-analyzer-enabling-elite-laboratory-performance-with-no-daily-maintenance-301824151.html

SOURCE Beckman Coulter Diagnostics

News Provided by Canada Newswire via QuoteMedia

danaher dhr nyse:dhr life science investing Life Science Investing

DHR

Discovery Harbour Approved All Resolutions at Annual and Special Meeting

Discovery Harbour Resources Corp. (TSXV: DHR) (OTC Pink: DCHRF) (FSE: 4GW) (the "Company" or "Discovery Harbour") shareholders approved all resolutions at the Company's annual and special meeting which was held on May 5, 2023. Details of these matters are disclosed in the management information circular for the meeting dated March 23, 2023, and posted under the company's profile on SEDAR.

At the meeting, shareholders elected the director nominees as listed in the Company's information circular, being Mark Fields, Richard Gilliam, Andrew Hancharyk and Rodney Stevens. The reappointment of Manning Elliott LLP, Chartered Professional Accountants, as auditor of the Company was approved by the shareholders as was the ratification and re-approval of the amended and restated 10% rolling stock option plan.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

ALDEVRON ANNOUNCES EXPANSION OF mRNA PRODUCTION CAPABILITY

Will offer mRNA cGMP Production from Master Cell Bank to Drug Product Made Possible with Precision Nanosystems and Cytiva

Aldevron, a leading global manufacturer of DNA, RNA and proteins used in cell and gene therapies and vaccine development, will expand its mRNA production capabilities to include lipid nanoparticle (LNP) encapsulation and aseptic fill-finish capabilities enabling mRNA cGMP manufacturing services from Master Cell Bank through to Drug Product. This new capability will support the production of therapeutic-scale clinical and commercial-stage mRNA therapies for cancers and genetic diseases, and clinical-stage vaccines for infectious diseases.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Danaher Reports First Quarter 2023 Results

Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the first quarter 2023. Net earnings refer to net earnings attributable to common shareholders.

For the quarter ended March 31, 2023 net earnings were $1.4 billion , or $1.94 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $2.36 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

INN Video: Ian Graham of Discovery Harbour Resources

Discovery Harbour Resources Corp. (TSXV:DHR) President and CEO, Ian Graham, spoke with Resource Investing News on its flagship project, Wabassi, located in northern Ontario. “We’ve put our arms around an entire Greenstone Belt hosted VMS Mineral District. This is, as far as I’m aware, Canada’s most recent discovery of a new mineral district,” states Mr. Graham. In 2013, investors can expect the mobilization of drilling on the project, with news expected to come out in July. “Based on that news, we will be financing the Company a little further in the fall,” Mr. Graham says.

Keep reading...Show less

Successful Maiden Dosing of TRP-8803 (IV-Infused Psilocin) Completed in Global First

Tryptamine Therapeutics Limited (‘Tryp’ or the ‘Company’) (ASX: TYP), a clinical-stage biotechnology company focused on the development of an innovative and scalable intravenous-infused psilocin formulation which may be used in conjunction with psychotherapy to address significant unmet medical needs, is pleased to advise that it has successfully and safely completed the world’s first participant dosing using TRP-8803 (IV-infused psilocin) in a patient in Adelaide, South Australia.

Keep reading...Show less

Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies

Bexicaserin achieved an overall median seizure reduction of 56.1% in countable motor seizures over an approximate 6-month treatment period; participants randomized to the PACIFIC placebo group achieved a median seizure reduction of 57.3%
Favorable safety and tolerability results observed
100% of participants who completed the PACIFIC Study entered the OLE
End of Phase 2 Meeting scheduled for this summer

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive interim results from its ongoing 52-week open-label extension of the PACIFIC Study evaluating bexicaserin (LP352) in participants ages 12-65 years old with Developmental and Epileptic Encephalopathies.

"We are thrilled to see a sustained, durable response in seizure reduction and a favorable safety and tolerability profile across a broad range of DEE patients. Additionally, we saw compelling seizure reduction in the PACIFIC placebo patients who transitioned to bexicaserin in the OLE. These data provide further support to bexicaserin's potential to offer a highly differentiated and best-in-class profile," stated Dr. Randall Kaye, Longboard's Chief Medical Officer.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver in Milan

SZN-043 is a novel biotherapeutic shown to potentiate Wnt signaling and induce proliferation of hepatocytes in preclinical models

Treatment with SZN-043 in the Phase 1a trial was safe and well tolerated in healthy volunteers and patients with a history of liver cirrhosis

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Annexon Announces Pricing of $125 Million Underwritten Public Offering

Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced the pricing of its previously announced underwritten public offering of 13,001,120 shares of its common stock at a price to the public of $6.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 7,000,000 shares of common stock at a purchase price of $6.249 per share, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (INKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 12, 2024, and will be conducted in a virtual format only. Registration for attendees will start at 9:15 a.m. ET.

To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/INKT2024 and enter the 16-digit control number found in their proxy materials. Guests may also access the meeting in listen-only mode. No control number is required for guests.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024

97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study

EASL Presentations Continue to Support Best-in-Class Potential with High Antiviral Potency, Short Treatment Duration, Low Risk of Drug Interaction and High Barrier to Resistance

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Danaher Corporation AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS
($ and shares in millions, except per share amounts)
(unaudited)

	Three-Month Period Ended
	March 31, 2023	April 1, 2022
Sales	{replace1}nbsp; 7,167	{replace1}nbsp; 7,688
Cost of sales	(2,797)	(2,983)
Gross profit	4,370	4,705
Operating costs:
Selling, general and administrative expenses	(2,147)	(2,092)
Research and development expenses	(429)	(441)
Operating profit	1,794	2,172
Nonoperating income (expense):
Other income (expense), net	24	(20)
Interest expense	(68)	(54)
Interest income	48	1
Earnings before income taxes	1,798	2,099
Income taxes	(348)	(374)
Net earnings	1,450	1,725
Mandatory convertible preferred stock dividends	(21)	(41)
Net earnings attributable to common stockholders	{replace1}nbsp; 1,429	{replace1}nbsp; 1,684
Net earnings per common share:
Basic	{replace1}nbsp; 1.96	{replace1}nbsp; 2.35
Diluted	{replace1}nbsp; 1.94	{replace1}nbsp; 2.31
Average common stock and common equivalent shares outstanding:
Basic	729.4	716.3
Diluted	737.2	737.7

Danaher Corporation RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
Diluted Net Earnings Per Common Share and Adjusted Diluted Net Earnings Per Common Share ¹

	Three-Month Period Ended
	March 31, 2023	April 1, 2022
Diluted Net Earnings Per Common Share (GAAP)	{replace1}nbsp; 1.94	{replace1}nbsp; 2.31
Amortization of acquisition-related intangible assets ^A	0.52	0.52
Fair value net (gains) losses on investments ^B	(0.03)	0.03
Separation costs ^C	0.04	—
Loss on partial settlement of a defined benefit plan ^D	—	0.01
Impairments and other charges ^E	—	0.06
Tax effect of the above adjustments ^F	(0.10)	(0.11)
Discrete tax adjustments ^G	(0.01)	(0.06)
Adjusted Diluted Net Earnings Per Common Share (Non-GAAP)	{replace1}nbsp; 2.36	{replace1}nbsp; 2.76

	Three-Month Period Ended
	March 31, 2023	April 1, 2022
Pretax	{replace1}nbsp; 384	{replace1}nbsp; 386
After-tax	310	311

	Three-Month Period Ended
	March 31, 2023	April 1, 2022
Pretax	{replace1}nbsp; (22)	{replace1}nbsp; 24
After-tax	(17)	18


^C	Costs incurred in the three-month period ended March 31, 2023 related to preparation for the anticipated separation of the Company's Environmental & Applied Solutions business primarily related to professional fees for legal, tax, finance and information technology services and duplicative general and administrative costs ($28 million pretax as reported in this line item, $25 million after-tax).

^D	Loss on a partial settlement of a defined benefit plan as a result of the transfer of a portion of the Company's non-U.S. pension liabilities related to one defined benefit plan to a third-party in the three-month period ended April 1, 2022 ($10 million pretax as reported in this line item, $9 million after-tax).

^E	Charges incurred primarily related to impairments of accounts receivable and inventory as well as accruals for contractual obligations in Russia incurred in the three-month period ended April 1, 2022 ($43 million pretax as reported in this line item, $40 million after-tax).

^F	This line item reflects the aggregate tax effect of all nontax adjustments reflected in the preceding line items of the table. In addition, the footnotes above indicate the after-tax amount of each individual adjustment item. Danaher estimates the tax effect of each adjustment item by applying Danaher's overall estimated effective tax rate to the pretax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires application of a specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment. The MCPS dividends are not tax deductible and therefore the tax effect of the adjustments does not include any tax impact of the MCPS dividends.

^G	Discrete tax adjustments and other tax-related adjustments for the three-month period ended March 31, 2023, include the impact of net discrete tax benefits of $5 million related primarily to excess tax benefits from stock-based compensation and the release of reserves for uncertain tax positions due to the expiration of statutes of limitation, partially offset by tax costs related to the separation of the Environmental & Applied Solutions business and changes in estimates associated with prior period uncertain tax positions. Discrete tax adjustments and other tax-related adjustments for the three-month period ended April 1, 2022, include the impact of net discrete tax benefits of $41 million related primarily to excess tax benefits from stock-based compensation and the changes in estimates associated with prior period uncertain tax positions.


¹	Each of the per share adjustment amounts above have been calculated assuming the Mandatory Convertible Preferred Stock ("MCPS") had been converted into shares of common stock.

Notes to Reconciliation of GAAP to Non-GAAP Financial Measures

^A	Amortization of acquisition-related intangible assets in the following historical periods (only the pretax amounts set forth below are reflected in the amortization line item above):


^B	Net (gains) losses on the Company's equity and limited partnership investments recorded in the following historical periods (only the pretax amounts set forth below are reflected in the fair value net (gains) losses on investments line above):

Average and Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding
(shares in millions)

	Three-Month Period Ended
	March 31, 2023	April 1, 2022
Average common stock and common equivalent shares outstanding - diluted (GAAP) ²	737.2	737.7
Converted shares ³	8.6	8.6
Adjusted average common stock and common equivalent shares outstanding - diluted (non-GAAP)	745.8	746.3


²	The impact of the MCPS Series B calculated under the if-converted method was anti-dilutive for the three-month periods ended March 31, 2023 and April 1, 2022, and as such 8.6 million shares underlying the MCPS Series B were excluded from the calculation of diluted EPS in both periods and the related MCPS Series B dividends of $21 million were included in the calculation of net earnings for diluted EPS for the periods.

	The impact of the MCPS Series A calculated under the if-converted method was dilutive for the three-month period ended April 1, 2022, and as such 11.0 million shares underlying the MCPS Series A were included in the calculation of diluted EPS in the three-month period and the related MCPS Series A dividends of $20 million were excluded from the calculation of net earnings for diluted EPS.

³	The number of converted shares assumes the conversion of all MCPS and issuance of the underlying shares applying the "if-converted" method of accounting and using an average 20 trading-day trailing Volume Weighted Average Price ("VWAP") of $246.26 and $281.28 as of March 31, 2023 and April 1, 2022, respectively.

Sales (Decline) Growth by Segment, Core Sales (Decline) Growth by Segment and Base Business Core Sales Growth by Segment

	% Change Three-Month Period Ended March 31, 2023 vs. Comparable 2022 Period
		Segments
	Total Company	Biotechnology	Life Sciences	Diagnostics	Environmental & Applied Solutions
Total sales (decline) growth (GAAP)	(7.0) %	(16.0) %	2.5 %	(10.0) %	5.0 %
Impact of:
Acquisitions/divestitures	— %	— %	(1.0) %	— %	(0.5) %
Currency exchange rates	3.0 %	3.0 %	3.5 %	2.5 %	2.0 %
Core sales (decline) growth (non-GAAP)	(4.0) %	(13.0) %	5.0 %	(7.5) %	6.5 %
Impact of COVID-19 related testing, vaccines and therapeutics	10.0 %	+Low-teens	+Low-single digit	+High-teens	— %
Base business core sales growth (non-GAAP)	6.0 %	Flat	+High-single digit	+Low-double digit	6.5 %

Forecasted Core Sales (Decline) Growth and Base Business Core Sales Growth

The Company provides forecasted sales only on a non-GAAP basis because of the difficulty in estimating the other components of GAAP revenue, such as currency translation, acquisitions and divested product lines.

	% Change Three-Month Period Ending June 30, 2023 vs. Comparable 2022 Period	% Change Year Ending December 31, 2023 vs. Comparable 2022 Period
Core sales (decline) growth (non-GAAP)	-High-single digit	-High-single digit
Impact of COVID-19 related testing, vaccines and therapeutics	+Low-double digit	+Low-double digit
Base business core sales growth (non-GAAP)	+Mid-single digit	+Mid-single digit

Operating Profit Margins and Year-Over-Year Core Operating Margin Changes

			Segments
		Total Company	Biotechnology	Life Sciences	Diagnostics	Environmental & Applied Solutions
Three-Month Period Ended April 1, 2022 Operating Profit Margins (GAAP)		28.30 %	36.10 %	19.10 %	33.50 %	20.30 %
	First quarter 2023 impact from operating profit margins of businesses that have been owned for less than one year	(0.15)	(0.15)	(0.45)	—	0.15
	First quarter 2022 impairments of accounts receivable and inventory as well as accruals for contractual obligations in Russia	0.55	0.60	1.45	0.10	0.10
	First quarter 2023 costs incurred related to preparation for the anticipated separation of the Company's Environmental & Applied Solutions business	(0.40)	—	—	—	—
Year-over-year core operating profit margin changes for the first quarter 2023 (defined as all year-over-year operating profit margin changes other than the changes identified in the line items above) (non-GAAP)		(3.30)	(4.55)	(1.30)	(5.10)	3.95
Three-Month Period Ended March 31, 2023 Operating Profit Margins (GAAP)		25.00 %	32.00 %	18.80 %	28.50 %	24.50 %

Cash Flow and Free Cash Flow
($ in millions)

	Three-Month Period Ended		Year-over-Year Change
	March 31, 2023	April 1, 2022	Year-over-Year Change
Total Cash Flows:
Net cash provided by operating activities (GAAP)	{replace1}nbsp; 1,947	{replace1}nbsp; 1,968
Total cash used in investing activities (GAAP)	{replace1}nbsp; (304)	{replace1}nbsp; (503)
Total cash used in financing activities (GAAP)	{replace1}nbsp; (262)	{replace1}nbsp; (274)

Free Cash Flow:
Net cash provided by operating activities (GAAP)	{replace1}nbsp; 1,947	{replace1}nbsp; 1,968	~ (1.0)%
Less: payments for additions to property, plant & equipment (capital expenditures) (GAAP)	(275)	(250)
Plus: proceeds from sales of property, plant & equipment (capital disposals) (GAAP)	—	2
Free cash flow (non-GAAP)	{replace1}nbsp; 1,672	{replace1}nbsp; 1,720	~ (3.0)%

Beckman Coulter Unveils Next Generation Immunoassay Analyzer Enabling Elite Laboratory Performance with No Daily Maintenance

Latest News

Latest Press Releases

Related News

TOP STOCKS